Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.06
+0.18001.21%
Pre-market: 15.150.0859+0.57%07:00 EDT
Volume:2.53M
Turnover:38.18M
Market Cap:3.03B
PE:-18.22
High:15.22
Open:15.05
Low:14.91
Close:14.88
52wk High:16.20
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.92
T/O Rate:1.29%
Dividend:1
Dividend Rate:6.64%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:0.98
PE(LYR):-10.53

Loading ...

Press Release: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Dow Jones
·
Aug 06

Harmony Biosciences Says New Data Supports Neurology Pipeline

Benzinga Earnings
·
Aug 05

Park Hotels & Resorts Inc Expected to Post Earnings of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Earning Preview: Park Hotels & Resorts Inc. this quarter’s revenue is expected to decrease by 0.89%, and institutional views are neutral-to-cautious

Earnings Agent
·
Jul 31

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

GlobeNewswire
·
Jul 28

Press Release: Samsung Epis Holdings Reports Second Quarter and Half-year 2026 Financial Results

Dow Jones
·
Jul 24

How Investors Are Reacting To Park Hotels & Resorts (PK) New Value Rating Amid Cost Pressures

Simply Wall St.
·
Jul 23

Park Hotels Reopens Royal Palm South Beach Miami After USD 100 Million Renovation

Reuters
·
Jul 23

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

GlobeNewswire
·
Jul 21

Is Park Hotels & Resorts (PK) Undervalued Following Positive Analyst Sentiment?

Simply Wall St.
·
Jul 21

Park Hotels & Resorts is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 18

Lawyer Denies Febrie Adriansyah Received Money from Tan Kian

Tempo
·
Jul 18

Morgan Stanley Adjusts PT on Park Hotels & Resorts to $11 From $10.50, Maintains Equalweight Rating

MT Newswires Live
·
Jul 17

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

GlobeNewswire
·
Jul 16

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

GlobeNewswire
·
Jul 12

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

GlobeNewswire
·
Jul 12

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

GlobeNewswire
·
Jul 08

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

GlobeNewswire
·
Jul 07

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

GlobeNewswire
·
Jun 29

PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark

GlobeNewswire
·
Jun 25